Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,253.7
6.5 (0.20%)

 

  • STI Straits Times Index
    3,253.7
    6.5 (0.20%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,577.2
    -10.1 (-0.64%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    28,341.0
    355.7 (1.27%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,060.8
    8.6 (0.28%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    24,031.3
    166.8 (0.70%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,230.1
    -8.0 (-0.13%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,267.2
    27.6 (1.23%)
    Index delayed 20 minutes
  • XAO XAO
    7,249.0
    68.5 (0.95%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,503.3M
  • Value: 865.7M
  • Rise: 146
  • Fall: 167
  • Unch: 506

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Medtecs Intl0.099+0.007
AsiaMedic0.017-0.001
Healthway Med0.043+0.003
P5 Capital0.034-0.001
Ntegrator Intl0.016+0.003
AusGroup^0.044-0.001
Thomson Medical0.063-
YZJ Shipbldg SGD1.090-0.010
DISA0.003-
Golden Agri-Res0.235+0.005

World Indices

World Indices
Name Last Change
Nasdaq 9,370.8 -18.1
HSI 28,341.0 +355.7
HSCEI 11,174.7 +204.6
Jakarta 6,230.1 -8.0
Nikkei 225 24,031.3 +166.8
SSE Comp 3,060.8 +8.6
Shanghai A 3,207.1 +9.0
Shanghai B 257.5 +0.2
PSE Comp 0.0
KOSPI 2,267.2 +27.6

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS
Updated on 21 Jan 2020 (End of trading day)
Last (USD): 139.900 Change: +0.770 High: 142.335 Remarks: -
Change (%): +0.55 Low: 138.720
Open 138.720 Yesterday's Close 139.13
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 104,722 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -3.19847 Trailing EPS (USD) e -4.23223 NAV (USD) b 16.0208
PE a - Trailing PE f - Price / NAV b 8.7324
Dividend (USD) d - Cash In Hand (USD) g 16.3834 Issued & Paid-up Shares c 47,986,000
Dividend Yield (%) d - Price / Cash In Hand g 8.539 Treasury Shares h -
Beta - 75 Daysi 1.497 R-Squared - 75 Days(%)i 5.71 Market Cap (M) 6,713.241
Beta - 500 Daysi 0.121 R-Squared - 500 Days (%)i 0.09 Enterprise Value (M) 5,968.406
Piotroski F Score 2 Exchange Code ASND Par Value ( $ ) n.a.
52 Weeks Volatility (%) 64.07 Free Float (%) 91.9
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 09 Jan 2020.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 13 Jul 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS NASDAQ 6,713.241 - - 8.7324 -
Industry Biotechnology NASDAQ 2,828.832 67.616 92.382 6.0573 0.867
Local Peer AMGEN INC NASDAQ 141,178.118 16.819 17.501 12.9201 2.355
Local Peer GILEAD SCIENCES INC NASDAQ 79,236.345 14.525 29.423 3.8457 3.689
Local Peer VERTEX PHARMACEUTICAL NASDAQ 60,170.529 28.702 28.068 11.4536 -
Local Peer BIOGEN INC NASDAQ 51,821.138 11.696 9.604 3.7026 -
Local Peer ILLUMINA INC NASDAQ 48,264.510 58.432 49.604 10.8728 -
Local Peer REGENERON PHARMACEUTICALS INC NASDAQ 39,933.892 16.337 18.624 3.8016 -
Local Peer ALEXION PHARMACEUTICAL INC NASDAQ 25,008.096 322.269 17.009 2.4122 -
Local Peer SEATTLE GENETICS INC NASDAQ 18,624.517 - - 10.4655 -
Local Peer INCYTE CORPORATION NASDAQ 16,940.974 154.722 41.833 6.9931 -
Local Peer BIOMARIN PHARMACEUTICAL NASDAQ 15,726.169 - - 5.1152 -
Local Peer GALAPAGOS NV SPON ADR REPR 1 ORD SHS NASDAQ 15,434.720 - 49.732 5.5843 -
Local Peer ALNYLAM PHARMACEUTICALS INC NASDAQ 13,153.590 - - 8.1848 -
Other Local Peers BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), EXACT SCIENCES CORP (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), 10X GENOMICS INC (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), MODERNA INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), EXELIXIS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), REPLIGEN CORP (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), IMMUNOMEDICS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), FIBROGEN INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), NATERA INC (NASDAQ), UNIQURE N.V. (NASDAQ), KODIAK SCIENCES INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), EPIZYME INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), SYNTHORX INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), XENCOR INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), VIELA BIO INC (NASDAQ), ARVINAS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), INSMED INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), REGENXBIO INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), CORTEXYME INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), ALECTOR INC (NASDAQ), VERACYTE INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), NEXTCURE INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), DERMIRA INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), OPKO HEALTH INC (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), XBIOTECH INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), INTREXON CORP (NASDAQ), RADIUS HEALTH INC (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), OMEROS CORP (NASDAQ), NANTKWEST INC (NASDAQ), AVROBIO INC (NASDAQ), CYTOKINETICS INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), RETROPHIN INC (NASDAQ), IMMUNOGEN INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), ARDELYX INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), KURA ONCOLOGY INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), MACROGENICS INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), AGENUS INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), MERUS B V (NASDAQ), BELLUS HEALTH INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), CABALETTA BIO INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), COMPUGEN (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), PERSONALIS INC (NASDAQ), RECRO PHARMA INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), NEUROINSIGHTS NEUROTECH (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), IVERIC BIO INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), MEDICINOVA INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), GERON CORP (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), KAMADA (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), AFFIMED N V (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), XOMA CORP (NASDAQ), GLYCOMIMETICS INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), CHIASMA INC (NASDAQ), IMV INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), ATHERSYS INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), ARAVIVE INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), NOVAVAX INC (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), CONTRAFECT CORP (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), SAVARA INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), VERASTEM INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), CHIMERIX INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), ADURO BIOTECH INC (NASDAQ), OTONOMY INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), SESEN BIO INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), COHBAR INC (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), SYNLOGIC INC (NASDAQ), INFLARX N V (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), ORGENESIS INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), TREVENA INC (NASDAQ), EQUILLIUM INC (NASDAQ), VERMILLION INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), VACCINEX INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), INMUNE BIO INC (NASDAQ), ADVAXIS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), CURIS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), RESTORBIO INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), ZAFGEN INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), EVOGENE LTD (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), SOLIGENIX INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), OCUGEN INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), BIOCARDIA INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), BIONANO GENOMICS INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), ATYR PHARMA INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), VAXART INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), PRECIPIO INC (NASDAQ), SENESTECH INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), BIOCEPT INC (NASDAQ), TOCAGEN INC (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), TROVAGENE INC (NASDAQ), OPGEN INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), BENITEC BIOPHARMA LTD SPON ADS EA REPR 200 ORD SHS(POST SPLIT) (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), SENECA BIOPHARMA INC (NASDAQ), SPHERIX INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ)
Global Peer CSL ASX 138,131.100 51.485 51.485 18.4589 0.872
Global Peer AMGEN-T HKEx 594,184.000 9.032 9.399 6.9364 4.385
Global Peer AGILENT TECHNOLOGIES INC NYSE 27,795.499 87.961 25.953 5.8541 0.682
Global Peer SINO BIOPHARM HKEx 151,866.775 14.173 14.710 4.5227 0.606
Global Peer WUXI BIO HKEx 134,349.414 179.875 140.620 13.8295 -
Global Peer BEIGENE HKEx 102,173.400 - - 10.1944 -
Global Peer Lonza SGX 5,937.453 7.663 9.330 0.6935 4.766
Global Peer GENSCRIPT BIO HKEx 34,257.426 206.015 - 9.6607 -
Global Peer 3SBIO HKEx 28,955.658 19.141 23.298 2.8539 -
Global Peer EMERGENT BIOSOLUTIONS INC NYSE 2,959.088 47.194 688.160 2.8590 -
Other Global Peers HAOHAI BIOTEC (HKEx), ALPHAMAB-B (HKEx), MYOVANT SCIENCES LTD (NYSE), POLYNOVO LIMITED (ASX), FRONTAGE (HKEx), AVITA MEDICAL LTD (ASX), CKLIFE SCIENCES (HKEx), MESOBLAST LTD (ASX), VIVA BIOTECH (HKEx), ASCENTAGE-B (HKEx), KADMON HLDGS INC (NYSE), SINOMAB BIO-B (HKEx), ARCUS BIOSCIENCES INC (NYSE), ASCLETIS-B (HKEx), ESSEX BIO-TECH (HKEx), LEE'S PHARM (HKEx), PFENEX INC (NYSE American), NEXT SCIENCE LTD (ASX), DPHARMA (Bursa), TELIX PHARMACEUTIC (ASX), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), BBI LIFE SCI (HKEx), NANOVIRICIDES INC (NYSE American), NEUREN PHARMACEUTICALS LTD (ASX), RESAPP HEALTH LIMITED (ASX), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), PYC THERAPEUTICS LIMITED (ASX), ENZO BIOCHEM INC (NYSE), UNI-BIO GROUP (HKEx), LINEAGE CELL THERAPEUTICS INC (NYSE American), 22ND CENTURY GROUP INC (NYSE American), IMUGENE LIMITED (ASX), PALATIN TECHNOLOGIES INC (NYSE American), CEL-SCI CORP (NYSE American), CYNATA THERAPEUTICS LTD (ASX), IMMUTEP LTD (ASX), ONCOSIL MEDICAL LIMITED (ASX), SYNTHETIC BIOLOGICS INC (NYSE American), ORTHOCELL LIMITED (ASX), CT ENTERPRISE (HKEx), ISORAY INC (NYSE American), INVEX THERAPEUTICS LTD NPV (ASX), BIOSINO BIO-TEC (HKEx), ANTEOTECH LIMITED (ASX), KAZIA THERAPEUTICS LIMITED (ASX), MEMPHASYS LTD (ASX), BIOTRON (ASX), BIONOMICS LTD (ASX), REGENT PACIFIC (HKEx), ACTINOGEN MEDICAL LTD (ASX), ARMATA PHARMACEUTICALS INC (NYSE American), GENETIC TECHNOLOGIES (ASX), TALI DIGITAL LIMITED (ASX), ORAGENICS INC (NYSE American), EXTRAWELL PHAR (HKEx), ACTINIUM PHARMACEUTICALS INC (NYSE American), IBIO INC (NYSE American), INDIA GLOBALIZATION CAPITAL INC (NYSE American), RHINOMED LIMITED (ASX), CCP TECHNOLOGIES LTD (ASX), PROTEOMICS INTL LABORATORIES LTD (ASX), IMMURON LIMITED (ASX), PATRYS LIMITED (ASX), CELLMID LIMITED (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), Suntar Eco-City^ (SGX), REGENEUS LTD (ASX), HOLISTA COLLTECH LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), ANATARA LIFESCIENCES LTD (ASX), ADALTA LTD (ASX), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), NOVABAY PHARMACEUTICALS INC (NYSE American), SIENNA CANCER DIAGNOSTICS LTD (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), BENITEC BIOPHARMA LTD (ASX), BIOXYNE LIMITED (ASX), AUSTRALIAN PRIMARY HEMP LTD (ASX), LIVING CELL TECHNOLOGIES (ASX), MEDIBIO LIMITED (ASX), QT Vascular (SGX), MGRC (Bursa), HAO WEN HLDGS (HKEx), AIM IMMUNOTECH INC (NYSE American), TBG DIAGNOSTICS LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), NANOLLOSE LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), FACTOR THERAPEUTICS LIMITED (ASX), BPH ENERGY LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.700
+0.50 %
10 Days -+1.820
+1.32 %
20 Days -+8.490
+6.46 %
Medium Term Return 3 Months -+34.300
+32.48 %
6 Months -+24.540
+21.27 %
1 Year -+66.880
+91.59 %
Long Term Return 2 Years -+85.730
+158.26 %
3 Years -+118.780
+562.41 %
5 Years -+121.070
+642.96 %
Annualised Return Annualised --
+49.35 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 66.115 - 142.940 Change From 1 Year Low +73.785 % Change From 1 Year Low (%) +111.60
Change From 1 Year High -3.040 % Change From 1 Year High (%) -2.13
2 Years Range 48.000 - 142.940 Change From 2 Years Low +91.900 % Change From 2 Years Low (%) +191.46
Change From 2 Years High -3.040 % Change From 2 Years High (%) -2.13
5 Years Range 11.920 - 142.940 Change From 5 Years Low +127.980 % Change From 5 Years Low (%) +1073.66
Change From 5 Years High -3.040 % Change From 5 Years High (%) -2.13
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market. The company was founded by Jan Moller Mikkelsen and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.

Historical Price Data

Date Open High Low Close Volume VWAP
21 Jan 2020 138.720 142.335 138.720 139.900 104,722 -
17 Jan 2020 140.150 141.881 136.670 139.130 216,784 -
16 Jan 2020 139.630 140.900 138.060 140.470 92,710 -
15 Jan 2020 139.260 142.940 138.520 139.200 141,216 -
14 Jan 2020 137.560 139.600 136.176 138.820 248,484 -
13 Jan 2020 137.720 139.835 135.360 137.880 224,148 -
10 Jan 2020 139.880 141.645 136.996 137.350 328,724 -
09 Jan 2020 138.500 140.200 137.000 139.380 206,017 -
08 Jan 2020 134.970 139.000 133.250 138.080 272,518 -
07 Jan 2020 134.120 134.990 131.810 134.710 218,482 -
06 Jan 2020 136.260 136.494 129.400 134.290 341,719 -
03 Jan 2020 140.000 140.540 135.825 137.130 169,267 -
02 Jan 2020 140.540 142.000 137.040 141.130 436,363 -
31 Dec 2019 136.160 140.150 135.220 139.120 191,490 -
30 Dec 2019 135.450 136.180 131.350 135.970 140,398 -
27 Dec 2019 138.000 138.000 132.540 135.070 274,197 -
26 Dec 2019 131.570 137.570 131.090 136.830 387,451 -
24 Dec 2019 129.900 131.830 128.560 131.410 66,024 -
23 Dec 2019 128.000 131.000 126.900 129.900 267,371 -
20 Dec 2019 124.760 127.500 123.455 127.000 299,444 -
19 Dec 2019 122.440 126.980 121.920 125.970 268,909 -
18 Dec 2019 124.350 124.627 120.700 122.770 200,570 -
Summary
Current 2 Weeks
(07 Jan 2020 to 21 Jan 2020)
134.120 142.940 131.810 139.900 2,053,805 -
Previous 2 Weeks
(20 Dec 2019 to 06 Jan 2020)
124.760 142.940 123.455 134.290 2,573,724 -
4 Weeks from
(21 Nov 2019 to 19 Dec 2019)
117.550 142.940 113.507 125.970 5,277,932 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.